Global Cancer Testing/Screening Market Size By Type (Lung Cancer, Blood Cancer), By Application (Hospitals and Clinics, Others), By Region, And Segment Forecasts, 2023 to 2032

lobal Cancer Testing & Screening Market Report Description

The Global Cancer Testing & Screening Market was valued at USD 17.4 billion in 2023 and is projected to surpass USD 32.8 billion by 2031, growing at a CAGR of 8.2% during the forecast period (2023-2031).

The growth of this market is primarily driven by the rising global cancer incidence, increasing awareness of early diagnosis, and the advancements in diagnostic technologies such as liquid biopsy, next-generation sequencing (NGS), and AI-driven screening platforms. Government initiatives promoting cancer screening programs, combined with growing investments from both public and private healthcare sectors, are further propelling market expansion.

As the global healthcare ecosystem shifts towards personalized medicine, cancer testing is becoming a cornerstone in early detection, risk assessment, and therapy selection, ensuring better patient outcomes and reducing overall healthcare costs.

Drivers

Rising Global Cancer Incidence

According to WHO estimates, cancer cases continue to rise globally due to aging populations, lifestyle changes, and environmental factors. This drives the need for regular screening and early detection to improve survival rates.

Technological Advancements in Diagnostics

Breakthroughs in liquid biopsy, molecular imaging, and AI-powered diagnostic tools are improving accuracy, reducing invasive procedures, and making cancer testing more accessible and cost-effective.

Government & NGO Awareness Programs

Increasing national screening initiatives, subsidized testing programs, and awareness campaigns have encouraged early diagnosis, boosting demand for cancer screening services.

Restraints

High Cost of Advanced Cancer Tests

Advanced diagnostic methods such as genomic profiling and NGS are expensive, limiting accessibility in low-income regions.

Lack of Skilled Healthcare Professionals

A shortage of trained oncologists and diagnostic specialists in emerging markets hinders the adoption of sophisticated cancer screening technologies.

Opportunities

Expansion in Emerging Markets

Rapid healthcare infrastructure development in Asia-Pacific, Latin America, and Africa offers significant opportunities for market players to establish cancer testing networks.

Rise of Liquid Biopsy & At-home Screening Kits

The growing popularity of non-invasive diagnostic methods and the development of at-home cancer screening solutions present a new revenue stream.

Integration with AI & Predictive Analytics

AI-driven analytics for predictive cancer screening and risk stratification will create disruptive growth opportunities for diagnostic companies.

Market by Test Type Insights

Imaging-based Tests (Mammography, MRI, CT scans) remain the most widely adopted due to their availability in hospitals and diagnostic centers.

Molecular Tests & Genomic Profiling are witnessing the fastest growth, driven by the demand for personalized cancer therapy.

Liquid Biopsy is emerging as a revolutionary non-invasive screening method with significant adoption potential during the forecast period.

Market by End-use Insights

Hospitals & Specialty Cancer Centers dominate the market as the primary hubs for cancer diagnosis and treatment.

Diagnostic Laboratories & Clinics are growing rapidly due to outsourcing of cancer testing services.

Home-based Testing & Telemedicine Platforms are expected to gain traction in developed markets, improving accessibility for patients.

Market by Regional Insights

North America accounted for the largest share in 2023, supported by advanced healthcare infrastructure, high awareness levels, and reimbursement policies for cancer screening.

Europe holds a significant share due to widespread government-funded screening programs.

Asia-Pacific is expected to witness the fastest growth, driven by rising cancer cases, growing healthcare expenditure, and increasing investments in diagnostic infrastructure in countries like China and India.

Competitive Scenario

Key players in the global cancer testing & screening market include:

Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Illumina Inc., Bio-Rad Laboratories, Exact Sciences Corporation, Guardant Health, and Qiagen N.V.

These companies focus on strategic collaborations, AI-based diagnostic platforms, mergers & acquisitions, and the expansion of molecular diagnostic solutions to strengthen their market position.

Recent Developments:

2024: Guardant Health launched a next-generation liquid biopsy test for early-stage cancer detection.

2023: Roche Diagnostics introduced AI-powered imaging tools integrated with mammography screening programs.

2023: Illumina Inc. partnered with a leading oncology network to expand genomic cancer testing services globally.

Scope of Work – Global Cancer Testing & Screening Market

Key Market Developments

January 2024: Exact Sciences expanded its portfolio with a multi-cancer early detection blood test.

October 2023: Siemens Healthineers acquired a leading molecular diagnostics startup specializing in cancer biomarkers.

July 2023: Abbott Laboratories launched a portable cancer screening device for remote and rural healthcare centers.

FAQs

What is the current market size of the Global Cancer Testing & Screening Market?

The market was valued at USD 17.4 billion in 2023.

What is the major growth driver of the Global Cancer Testing & Screening Market?

The major growth driver is the increasing global cancer burden and technological advancements in screening techniques.

Which is the largest region during the forecast period in the Global Cancer Testing & Screening Market?

North America is expected to remain the largest market due to advanced healthcare infrastructure and high screening awareness.

Which segment accounted for the largest market share in the Global Cancer Testing & Screening Market?

Imaging-based Tests held the largest share in 2023, while liquid biopsy is expected to grow the fastest.

Who are the key market players in the Global Cancer Testing & Screening Market?

Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Illumina Inc., and Guardant Health are the leading players.

Would you like me to also create a visually formatted PDF version of this report description for easy sharing? Or should I prepare another market report in the same format for a different topic?